GuidelineHormones (Athens, Greece)2025
Diagnosis and management of hypoparathyroidism: recommendations of the working group of the Bone Section of the Hellenic Endocrine Society.
Guideline in Hormones (Athens, Greece), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT07299838 (Real-World Data for Effectiveness and Safety of Palopegteriparatide in Patients With Chronic Hypoparathyroidism in Greece), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Real-World Data for Effectiveness and Safety of Palopegteriparatide in Patients With Chronic Hypoparathyroidism in Greece
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypoparathyroidism (HypoPT) is a rare endocrine disorder characterized by hypocalcemia accompanied by low or inappropriately normal parathyroid hormone (PTH) levels. The Bone Section of the Hellenic Endocrine Society reviewed the available evidence and the recent international guidelines and provided updated clinical practice recommendations for the diagnosis and optimal management of patients with HypoPT. Specifically, permanent post-surgical HypoPT should be considered if the disorder persists for more than 12 months after surgery, while in non-surgical cases, appropriate genetic testing should be applied, especially in young patients or those with syndromic features. In addition, the current report provides recommended and suggested laboratory and imaging examinations for the optimal management of patients with HypoPT. Concerning management, the panel recommends conventional therapy with calcium and vitamin D analogs as first-line treatment, while in patients with inadequate disease control, PTH replacement therapy should be considered with close monitoring. Finally, the challenges of the diagnosis and management of HypoPT in pregnancy are also discussed.
Indexed as
Identifiers
40576884What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.